InsiderTrades

Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2026-07-09 18:41:02 ET · period of report 2026-07-07 · accession 0001965808-26-000011 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-07-09 18:41 2026-07-07+ NBIX Delaet Ingrid Chief Regulatory Off M - OptEx $103.52 +14.6K 24.7K +144% +$1.51M
DMT 2026-07-09 18:41 2026-07-07+ NBIX Delaet Ingrid Chief Regulatory Off S - Sale+OE $178.65 -14.6K 16.2K -47% -$2.60M
DMT 2026-07-09 18:41 2026-07-07+ NBIX Delaet Ingrid Chief Regulatory Off M - OptEx $0.00 -14.6K 7,478 -66% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-07-07 M A 3,401 $103.52 19,626 D — —
2 Common Common Stock 2026-07-07 S D 3,401 $178.57 16,225 D — — (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3 Common Common Stock 2026-07-08 M A 2,737 $103.52 18,962 D — —
4 Common Common Stock 2026-07-08 S D 2,737 $178.54 16,225 D — — (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5 Common Common Stock 2026-07-09 M A 8,433 $103.52 24,658 D — —
6 Common Common Stock 2026-07-09 S D 8,433 $178.72 16,225 D — — (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F4) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7 Derivative Non-Qualified Stock Option 2026-07-07 M D 3,401 $0.00 18,648 D $103.52 · — to 2033-02-13 3,401 Common Stock (F5) The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.
8 Derivative Non-Qualified Stock Option 2026-07-08 M D 2,737 $0.00 15,911 D $103.52 · — to 2033-02-13 2,737 Common Stock (F5) The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.
9 Derivative Non-Qualified Stock Option 2026-07-09 M D 8,433 $0.00 7,478 D $103.52 · — to 2033-02-13 8,433 Common Stock (F5) The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.